Polymer Capital Management HK LTD Buys New Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Polymer Capital Management HK LTD purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,313 shares of the biopharmaceutical company's stock, valued at approximately $2,427,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ALNY. Larson Financial Group LLC raised its holdings in shares of Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 73 shares during the last quarter. R Squared Ltd acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $33,000. OFI Invest Asset Management purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $35,000. Versant Capital Management Inc increased its stake in Alnylam Pharmaceuticals by 77.6% in the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 83 shares in the last quarter. Finally, Quantbot Technologies LP boosted its position in shares of Alnylam Pharmaceuticals by 1,754.5% in the 3rd quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company's stock worth $56,000 after buying an additional 193 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ALNY has been the topic of a number of analyst reports. Scotiabank increased their price objective on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research note on Monday, March 31st. Needham & Company LLC restated a "buy" rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday. Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a report on Friday, March 21st. Sanford C. Bernstein decreased their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th. Finally, Citigroup upped their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research report on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $315.58.

Remove Ads

Alnylam Pharmaceuticals Price Performance

ALNY traded up $10.07 on Friday, reaching $236.35. The company had a trading volume of 561,977 shares, compared to its average volume of 857,994. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The company has a fifty day moving average of $253.86 and a 200-day moving average of $258.62. The company has a market capitalization of $30.75 billion, a P/E ratio of -108.08 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the business's stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares of the company's stock, valued at $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares in the company, valued at approximately $20,802,989.42. This represents a 1.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock valued at $19,958,097 in the last 90 days. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.